en
/
sv
About Elicera
Elicera in brief
Board
Team
Advisors
Elicera's history
Immuno-oncology
What is immuno-oncology?
CAR T-cell therapy
Oncolytic virus
Technology
CAR T-cell therapy
Challenges
Mode-of-action
Scientific publications
Pipeline
Pipeline
ELC-301
ELC-401
ELC-201
ELC-100
Clinical trials
Patent portfolio
Investors
Press Releases
Corporate Governance
the Share
Financial Reports
Financial Calendar
Events
Share issues
Analyst Coverage
News
News
Press Releases
Events
Contact
en
/
sv
News
2026
2025
2024
2023
2022
2021
2020
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Jan 17, 2024
2024
Press Release Non-regulatory
Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON
Non-regulatory Press Release
Read more
Jan 9, 2024
2024
Press Release Non-regulatory
Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand
Non-regulatory Press Release
Read more
Dec 22, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research
Non-regulatory Press Release
Read more
Dec 22, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application
Non-regulatory Press Release
Read more
Nov 30, 2023
2023
Press Release Regulatory
Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)
Regulatory Press Release
Read more
Nov 14, 2023
2023
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023
Regulatory Press Release
Read more
Oct 31, 2023
2023
Press Release Regulatory
Nomination Committee for Elicera therapeutics appointed
Regulatory Press Release
Read more
Sep 8, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform
Non-regulatory Press Release
Read more
Aug 29, 2023
2023
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023
Regulatory Press Release
Read more
Aug 10, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program
Non-regulatory Press Release
Read more
Jul 11, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform
Non-regulatory Press Release
Read more
May 16, 2023
2023
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023
Regulatory Press Release
Read more
Apr 28, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)
Non-regulatory Press Release
Read more
Apr 17, 2023
2023
Press Release Regulatory
Elicera Therapeutics publishes the annual report for 2022
Regulatory Press Release
Read more
Mar 6, 2023
2023
Press Release Non-regulatory
Erik Penser Bank initiates coverage on Elicera Therapeutics
Non-regulatory Press Release
Read more
Mar 1, 2023
2023
Press Release Regulatory
Elicera Therapeutics hires Erik Penser Bank as market maker
Regulatory Press Release
Read more
Feb 17, 2023
2023
Press Release Regulatory
Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022
Regulatory Press Release
Read more
Feb 7, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives
Non-regulatory Press Release
Read more
Jan 26, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma
Non-regulatory Press Release
Read more
Jan 23, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3
Non-regulatory Press Release
Read more
Previous
+ Load more
4 / 8
Sign up for Press Releases
By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy
here
.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our
Integrity policy
.
Deny
Accept